The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to ...

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget and issued a light sales view.

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...

DBS analyst Mark Kong CFA has maintained their bullish stance on MRNA stock, giving a Buy rating yesterday. Mark Kong CFA has given his Buy ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

Also, the trial treated patients in non-ICU wards, whereas patients with "COPD and acidemia requiring mechanical ventilation, and in particular those in whom intubation criteria are being monitored, ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Looking ahead to 2026-2028, Moderna will expand its commercial portfolio with first-in-class vaccines and therapeutics to address non-respiratory diseases, including cytomegalovirus, norovirus, ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibran ...